Physician profile
Sunil A Reddy
NPI 1578645057
$4,957.37
in general payments reported to CMS, 2019-2025
19 companies · $1,785 in 2025
The $1,785 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $1,060 · 2021: $87.86 · 2022: $295 · 2023: $507 · 2024: $385 · 2025: $1,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385 · Travel and Lodging: $1,084 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,385.20 |
| Travel and Lodging | $1,083.98 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $208.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunocore Limited | $1,254.33 | 2022-2025 | Kimmtrak |
| Varian Medical Systems, INC. | $960.00 | 2020 | |
| Pfizer INC. | $500.46 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $454.25 | 2019-2023 | |
| Emd Serono, INC. | $447.69 | 2019-2020 | |
| Galvanize Therapeutics, INC | $220.69 | 2023 | Aliya System |
| Taiho Oncology, INC. | $207.41 | 2025 | |
| Array Biopharma INC | $191.78 | 2019-2024 | Braftovi, Mektovi, Tukysa |
| Novocure INC. | $147.20 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $141.05 | 2025 | |
| Delcath Systems | $140.46 | 2024 | Hepzato Kit |
| Regeneron Pharmaceuticals, INC. | $115.89 | 2025 | Libtayo |
| Trisalus Life Sciences, INC. | $100.65 | 2023 | Trinav Infusion System |
| Celgene Corporation | $51.15 | 2025 | Zeposia |
| Eisai INC. | $24.36 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.